HC Wainwright Reiterates "Buy" Rating for Verastem, Inc. (VSTM)

The company last reported its quarterly results on Aug 14 AMC.

When it comes to the Analysis of a Stock, Price Target plays a vital role. The Stock now has a Weekly Volatility of 11.28% and Monthly Volatility of 8.69%.

VSTM has been the subject of a number of other reports. HC Wainwright set a $7.00 price objective on Verastem and gave the company a "buy" rating in a research note on Thursday, August 10th. Verastem has $6.50 highest and $6 lowest target. Jefferies Group LLC reaffirmed a "hold" rating and issued a $1.50 price target on shares of Verastem in a report on Wednesday, June 28th. They now have a Dollars 6 price target on the stock. Duvelisib, Verastem's lead drug candidate, is an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma being investigated for the treatment of hematologic cancers, including chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), indolent non-Hodgkin lymphoma (iNHL) and other T cell lymphomas. This company shares are -5.89% up from its target price of $4.63 and the current market capitalization stands at $179.63M. Verastem's 50-day average is $3.54 and its two hundred day average is $2.45.

(VSTM) escalated 0.41% and closed its last trading session at $4.94. The biopharmaceutical business posted ($0.36) EPS for the period, falling below Zacks' average forecast of ($0.34) by $0.02. on consensus, experts expect that Verastem to post ($1.38) EPS for the present financial year. For the current quarter Verastem Inc (NASDAQ:VSTM) has high EPS estimates of $-0.28 in contradiction of low EPS estimates of $-0.35.

ILLEGAL ACTIVITY WARNING: "Verastem, Inc". If you are reading this news story on another website, it was stolen and republished in violation of USA and global trademark and copyright legislation. The correct version of this story can be viewed at https://stocknewstimes.com/2017/09/08/verastem-inc-vstm-rating-increased-to-overweight-at-cantor-fitzgerald.html.

Quite a few hedge fund investors and institutional investors have modified to their stake in the share. Northern Trust Corp now owns 73,750 shares of the biopharmaceutical company's stock valued at $160,000 after buying an additional 21,178 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Verastem by 20.0% in the first quarter. Its book value per share for the most recent quarter is $1.3 while its price to book ratio for the same period is 3.8, as for as the company's cash per share for the most recent quarter is $1.59, however its price to cash per share ratio for the same period is 3.12. Howland Capital Management LLC increased its position in Verastem by 16.5% during the 2nd quarter. Howland Capital Management LLC now owns 294,007 shares of the biopharmaceutical company's stock worth $641,000 after purchasing an additional 41,616 shares during the last quarter. Alpine Woods Capital Investors LLC acquired a new stake in shares of Verastem in the second quarter worth $109,000. Northern Trust Corp grew its position in shares of Verastem by 40.3% in the 2nd quarter. However, the institutional investors are observed to own 91.70% of the total shares.

Verastem said its successful trial triggers a $6 million payment to Infinity Pharmaceuticals Inc from which it licensed duvelisib past year. The Firm is focused on discovering and developing drugs to improve outcomes for patients with cancer.



Latest news

Does Teva Pharmaceutical Industries Limited (TEVA) Present Much Upside ?
Equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current fiscal year. Over the past 50 days, Teva Pharmaceutical Industries Limited stock's -54.17% off of the high and 1.84% removed from the low.

League Final Day Preview - Plateau United, Mfm Seek to Be Champions
But two minutes into added time, Yahuza Bala scored what proved to be the victor as he got on the score sheet for El-Kanemi. It will be a straight fight between Enyimba and Akwa United for third place and a CAF Confederation Cup ticket next year.

Stocks Hitting New Technical Facts- trivago NV (NASDAQ:TRVG)
Therefore 45% are positive. trivago N.V. -... had 17 analyst reports since December 20, 2016 according to SRatingsIntel. The stock was trading at a distance of -38.48% from its 52-week highs and stands 37.22% away from its 52-week lows.

NFL Football Philadelphia Eagles at Washington Redskins Start Time, NFL Odds
That's how Norman played against Jeffery last Christmas Eve, when Jeffery had five catches for 92 yards for the Bears. I also don't expect too many wholesale changes schematically from this unit since Manusky was an internal promotion.

Power battle as Del Potro faces Thiem at US Open
NOTE: Please be aware that you will need an active Bet365 account to watch Juan Martin Del Potro v Dominic Thiem in US Open . As a result, I am expecting a hard fought contest.

Other news